1

PEER-REVIEWED ORIGINAL RESEARCH PUBLICATIONS

David Price

Research Articles 1. McKeever T, Price D, et al. Quadrupling inhaled gluococorticoid dose to abort asthma exacerbations. N Engl J Med 2018;

378(10): 902-910. [PubMed] [Full Text]

2. Price D, et al. Factors associated with appropriate inhaler use in patients with COPD – lessons from the REAL survey. Int J Chron Obstruct Pulmon Dis 2018; 13: 695-702. [PubMed] [Full Text]

3. Miravitlles M, Price DB, et al. Evaluation of criteria for clinical control in a prospective, international, multicenter study of patients with COPD. Respir Med 2018; 136: 8-14. [PubMed] [Full Text]

4. Price DB, et al. Real-life effectiveness and safety of Salbutamol Steri-neb™ vs. Ventolin Nebules® in preventing exacerbations in patients with COPD: historical cohort study. PLoS One 2018; 13(1): e0191404. [PubMed] [Full Text]

5. Kerkhof M, Price DB, et al. Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population. Thorax 2018; 73: 116-124. [PubMed] [Full Text]

6. Bosnic-Anticevich S, Price DB, et al. Inhaler technique mastery and maintenance in healthcare professionals trained on different devices. J Asthma 2018: 55(1): 79-88. [PubMed] [Full Text]

7. Bruton A, Price D, et al. Physiotherapy breathing retraining for asthma: a randomised controlled trial. Lancet Respir Med 2017. [PubMed] [Full Text]

8. Colice G, Price D, et al. The effect of DPP-4 inhibitors on asthma control: an administrative database study to evaluate a potential pathophysiological relationship. Pragmat Obs Res 2017; 8: 231-240. [PubMed] [Full Text]

9. Tan R, Price D, et al. Identifying the hidden burden of Allergic Rhinitis (AR) in community pharmacy: a global phenomenon. Asthma Res Pract 2017; 3: 8. [PubMed] [Full Text]

10. van der Molen T, Fletcher M, and Price D. Identifying patient attitudinal clusters associated with asthma control: the European REALISE survey. J Allergy Clin Immunol Pract 2017. [PubMed] [Full Text]

11. Smid DE, Price D, et al. Redefining cut-points for high symptom burden of the Global Initiative for Chronic Obstructive Lung Disease classification in 18,577 patients with chronic obstructive pulmonary disease. J Am Med Dir Assoc 2017; 8(12): 1097.e11–1097.e24. [PubMed] [Full Text]

12. Chapman S, Price D, et al. Modelling the effect of beliefs about asthma medication and treatment intrusiveness on adherence and preference for once-daily vs. twice-daily medication. NPJ Prim Care Respir Med 2017; 27(1): 61. [PubMed] [Full Text]

13. Price DB, et al. Fractional exhaled nitric oxide as a predictor of response to inhaled corticosteroids in patients with non-specific respiratory symptoms and insignificant bronchodilator reversibility: a randomised controlled trial. Lancet Respir Med 2017. [PubMed] [Full Text]

14. Bosnic-Anticevich S, Price D, et al. Lack of asthma and rhinitis control in general practitioner-managed patients prescribed fixed dose combination therapy in Australia. J Asthma 2017; 8: 1-11. [PubMed] [Full Text]

15. Carney AS, Price DB, et al. Seasonal patterns of oral antihistamine and intranasal corticosteroid purchases from Australian community pharmacies: a retrospective observational study. Pragmat Obs Res 2017; 8: 157-165. [PubMed] [Full Text]

16. Jones R, Price D, et al. The comparative effectiveness of initiating fluticasone/salmeterol combination therapy via pMDI versus DPI in reducing exacerbations and treatment escalation in COPD: a UK database study. Int J Chron Obstruct Pulmon Dis 2017; 12: 2445-2454. [PubMed] [Full Text]

17. Nibber A, Price D, et al. Validating the concept of COPD control: a real-world cohort study from the United Kingdom. COPD 2017; 14(5): 504-512. [PubMed] [Full Text]

18. Wan Yau Ming S, Price DB, et al. Initiating or changing to a fixed-dose combination of fluticasone propionate/formoterol over fluticasone propionate/salmeterol: a real-life effectiveness and cost impact evaluation. Respir Med 2017; 129: 199-206. [PubMed] [Full Text]

19. Barry LE, Price D, et al. The cost of systemic corticosteroid-induced morbidity in severe asthma: a health economic analysis. Respir Res 2017; 18(129). [PubMed] [Full Text]

20. Sonnappa S, Price DB, et al. Risk of pneumonia in obstructive lung disease: a real-life study comparing extra-fine and fine-particle inhaled corticosteroids. PLoS One 2017; 12(6): e0178112. [PubMed] [Full Text]

21. Price DB, et al. Real-life effectiveness and safety of the inhalation suspension budesonide comparator vs the originator product for the treatment of patients with asthma: a historical cohort study using a US health claims database. Pragmat Obs Res 2017; 8: 69-83. [PubMed] [Full Text]

22. Smith P, Price D, et al. Medication-related costs of rhinitis in Australia: a NostraData cross-sectional study of pharmacy purchases. J Asthma Allergy 2017; 10: 153-61. [PubMed] [Full Text]

23. Scadding G, Price D, et al. Multicentre, non-interventional study to assess the profile of patients with uncontrolled rhinitis prescribed a novel formulation of azelastine hydrochloride and fluticasone propionate in a single spray in routine clinical practice in the UK. BMJ Open 2017; 7: e014777. [PubMed] [Full Text]

24. Voorham J, Price DB, et al. Does co-payment for inhaler devices affect therapy adherence and disease outcomes? A historical, matched cohort study. Pragmat Obs Res 2017; 8: 31-41. [PubMed] [Full Text]

25. Usmani OS, Price DB, et al. A randomized pragmatic trial of changing to and stepping down fluticasone/formoterol in asthma. J Allergy Clin Immunol Pract 2017; 5(5): 1378-1387.e5. [PubMed] [Full Text]

26. Dollerup J, Price DB, et al. Cardiovascular risks in smokers treated with nicotine replacement therapy: a historical cohort study. Clin Epidemiol 2017; 9: 231-43. [PubMed] [Full Text]

27. Thomas V, Price DB, et al. Ipratropium/Salbutamol comparator versus originator for chronic obstructive pulmonary disease exacerbations: US observational cohort study using the Clinformatics™ health claims database. Pulm Ther 2017; 3(1): 187-205. [Full Text]

2

28. Souverein PC, Price D et al.; on behalf of the Respiratory Effectiveness Group's Adherence Working Group. Inhaled corticosteroid adherence patterns in a longitudinal asthma cohort. J Allergy Clin Immunol Pract 2017; 5(2): 448-456.e2. [PubMed] [Full Text]

29. Postma DS, Price DB, et al. Cohort analysis of exacerbation rates in adolescent and adult patients initiating inhaled corticosteroids for asthma: different dose-response profile by particle size. Pulm Ther 2017; 3(1): 113-124. [Full Text]

30. Burden A, Price DB, et al. An evaluation of exact matching and propensity score methods as applied in a comparative effectiveness study of inhaled corticosteroids in asthma. Pragmat Obs Res 2017; 8: 15-30. [PubMed] [Full Text]

31. Ryan D, Price D, et al.; on behalf of the Respiratory Effectiveness Group. Use of electronic medical records and biomarkers to manage risk and resource efficiencies. Eur Clin Respir J 2017; 4(1): 1293386. [PubMed] [Full Text]

32. Price DB, et al. Inhaler errors in the CRITIKAL study: type, frequency, and association with asthma outcomes. J Allergy Clin Immunol Pract 2017; 5(4): 1071-81.e9. [PubMed] [Full Text]

33. Murray CS, Price DB, et al. Comparative effectiveness of step-up therapies in children with asthma prescribed inhaled corticosteroids: a historical cohort study. J Allergy Clin Immunol Pract 2017; 5(4): 1082-1090.e7. [PubMed] [Full Text]

34. Pavord ID, Price D, et al. The impact of poor asthma control among asthma patients treated with inhaled corticosteroids plus long-acting β2- agonists in the United Kingdom: a cross-sectional analysis. NPJ Prim Care Respir Med 2017; 27: 17. [PubMed] [Full Text]

35. Rodrigo GJ, Price D, et al. LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis 2017; 12: 907-22. [PubMed] [Full Text]

36. Turner S, Price DB, et al.; Respiratory Effectiveness Group. Long-acting β-agonist in combination or separate inhaler as step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. J Allergy Clin Immunol Pract 2017; 5(1): 99–106.e3. [PubMed] [Full Text]

37. Guilbert TW, Price DB, et al.; in collaboration with the Respiratory Effectiveness Group. Real-life outcomes for patients with asthma prescribed spacers for use with either extrafine- or fine-particle inhaled corticosteroids. J Allergy Clin Immunol Pract 2017; 5(4): 1040-1049.e4. [PubMed] [Full Text]

38. J Bousquet, Price D, et al. Pilot study of mobile phone technology in allergic rhinitis in European countries. The MASK-rhinitis study. Allergy 2017. [PubMed] [Full Text]

39. Chisholm A, Price D, et al. Personalising care of adults with asthma from Asia: a modified e-Dephi consensus study to inform management tailored to attitude and control profiles. NPJ Prim Care Respir Med 2017; 27: 16089. [PubMed] [Full Text]

40. David-Wang A, Price D, et al.; for the REcognise Asthma and LInk to Symptoms and Experience (REALISE) Asia Working Group. Development and validation of an attitudinal-profiling tool for patients with asthma. Allergy Asthma Immunol Res 2017; 9(1): 43-51. [PubMed] [Full Text]

41. Bosnic-Anticevich S, Price DB, et al. The use of multiple respiratory inhalers requiring different inhalation techniques has an adverse effect on COPD outcomes. Int J Chron Obstruct Pulmon Dis 2017; 12: 59-71. [PubMed] [Full Text]

42. Blakey JD, Price DB, et al. Identifying risk of future asthma attacks using UK medical record data: a Respiratory Effectiveness Group initiative. J Allergy Clin Immunol 2016; 5(4): 1015-1024.e8. [PubMed] [Full Text]

43. Ställberg B, Price D, et al. The prevalence of comorbidities in COPD patients, and their impact on health status and COPD symptoms in primary care patients: a protocol for an UNLOCK study from the IPCRG. NPJ Prim Care Respir Med 2016; 26: 16069. [PubMed] [Full Text]

44. Price D, et al. First maintenance therapy for COPD in the UK between 2009 and 2012: a retrospective database analysis. NPJ Prim Care Respir Med 2016; 26: 16061. [PubMed] [Full Text]

45. Belhassen M, Price D, et al. Inappropriate asthma therapy — a tale of two countries: a parallel population-based cohort study. NPJ Prim Care Respir Med 2016; 26: 16076. [PubMed] [Full Text]

46. Skeggs A, Price D, et al. FourFold Asthma Study (FAST): a study protocol for a randomised controlled trial evaluating the clinical cost-effectiveness of temporarily quadrupling the dose of inhaled steroid to prevent asthma exacerbations. Trials 2016; 17: 499. [PubMed] [Full Text]

47. Postma DS, Price DB, et al. Asthma-related outcomes in patients initiating extrafine ciclesonide or fine-particle inhaled corticosteroids. Allergy Asthma Immunol Res 2017; 9(2): 116-25. [PubMed] [Full Text]

48. Dekhuijzen PNR, Price DB, et al. Incidence of oral thrush in patients with COPD prescribed inhaled corticosteroids: effect of drug, dose, and device. Respir Med 2016; 120: 54-63. [PubMed] [Full Text]

49. Price DB, et al. Metabolic effects associated with ICS in patients with COPD and comorbid type 2 diabetes: a historical matched cohort study. PLoS One 2016; 11(9): e0162903. [PubMed] [Full Text]

50. Halpin DMG, Price DB, et al. Eligibility of real-life patients with COPD for inclusion in trials of inhaled long-acting bronchodilator therapy. Respir Res 2016; 17(1): 120. [PubMed] [Full Text]

51. Price DB, et al. Historical cohort study examining comparative effectiveness of albuterol inhalers with and without integrated dose counter for patients with asthma or chronic obstructive pulmonary disease. J Asthma Allergy 2016; 9: 145-54. [PubMed] [Full Text]

52. Klimek L, Price D, et al. MP-AzeFlu provides rapid and effective allergic rhinitis control in real life: a pan-European study. Allergy Asthma Proc 2016; 37(5): 376-86. [PubMed] [Full Text]

53. Maleki-Yazdi MR, Price D, et al. Cost effectiveness of the long-acting β2-adrenergic agonist (LABA)/long-acting muscarinic antagonist dual bronchodilator indacaterol/glycopyrronium versus the LABA/inhaled corticosteroid combination salmeterol/fluticasone in patients with chronic obstructive pulmonary disease: analyses conducted for Canada, France, Italy, and Portugal. Appl Health Econ Health Policy 2016; 14(5): 579-94. [PubMed] [Full Text]

54. Lipworth B, Price DB, et al. Underuse of β-blockers in heart failure and chronic obstructive pulmonary disease. Heart 2016; 102(23): 1909-14. [PubMed] [Full Text]

55. Price DB, et al. UK prescribing practices as proxy markers of unmet need in allergic rhinitis: a retrospective observational study. NPJ Prim Care Respir Med 2016; 26:16033. [PubMed] [Full Text]

56. Happich M, Price D, et al. Excess costs associated with possible misdiagnosis of Alzheimer’s disease among patients with vascular dementia in a UK CPRD population. J Alzheimers Dis 2016; 53(1): 171–83. [PubMed] [Full Text]

3

57. Price DB, et al. Add-on LABA in a separate inhaler as asthma step-up therapy versus increased dose of ICS or ICS/LABA combination inhaler. ERJ Open Res 2016; 2(2). [PubMed] [Full Text]

58. van der Molen T, Price DB, et al. Effectiveness of initiating extrafine-particle versus fine-particle inhaled corticosteroids as asthma therapy in the Netherlands. BMC Pulm Med 2016; 16(1): 80. [PubMed] [Full Text]

59. Braido F, Price D, et al.; LIAISON Study Group. Determinants and impact of suboptimal asthma control in Europe: The InternationaL cross-sectIonAl and longitudinal assessment on aSthma cONtrol (LIAISON) study. Respir Res 2016; 17(1): 51. [PubMed] [Full Text]

60. Sastre J, Price D, et al. Insights, attitudes, and perceptions about asthma and its treatment: a multinational survey of patients from Europe and Canada. World Allergy Organ J 2016; 9: 13. [PubMed] [Full Text]

61. Upton J, Price D, et al. Asthma-specific health related quality of life of people in Great Britain: A national survey. J Asthma 2016; 26:1-8. [PubMed] [Full Text]

62. Price D, et al. Asthma in Asia: Physician perspectives on control, inhaler use and patient communications. J Asthma 2016; 53(7): 761-9. [PubMed] [Full Text]

63. Lee H, Price D, et al. Impacts of coexisting bronchial asthma on severe exacerbations in mild-to-moderate COPD: results from a national database. Int J Chron Obstruct Pulmon Dis 2016; 11(1): 775–83. [PubMed] [Full Text]

64. Lisspers K, Price D, et al. Are pharmacological randomised controlled clinical trials relevant to real-life asthma populations? A protocol for an UNLOCK study from the IPCRG. NPJ Prim Care Respir Med 2016; 26: 16016. [PubMed] [Full Text]

65. Jones RC, Price D, et al.; UNLOCK Group of the IPCRG. Multi-component assessment of chronic obstructive pulmonary disease: an evaluation of the ADO and DOSE indices and the global obstructive lung disease categories in international primary care data sets. NPJ Prim Care Respir Med 2016; 26: 16010. [PubMed] [Full Text]

66. Sweeney J, Price D, et al.; on behalf of the British Thoracic Society Difficult Asthma Network. Comorbidity in severe asthma requiring systemic corticosteroid therapy: cross-sectional data from the Optimum Patient Care Research Database and the British Thoracic Difficult Asthma Registry. Thorax 2016; 71(4): 339-46. [PubMed] [Full Text]

67. Fletcher M, Price D, et al. Patient reported burden of asthma on resource use and productivity across 11 countries in Europe. Adv Ther 2015; 32(4): 370-80. [PubMed] [Full Text]

68. Roche N, Price DB, et al. Cost-effectiveness of asthma step-up therapy as an increased dose of extrafine-particle inhaled corticosteroid or add-on long-acting beta2-agonist. Pulm Ther 2016; 2: 73-89. [Full Text]

69. Miravitlles M, Price D, et al. The relationship between 24-hour symptoms and COPD exacerbations and healthcare resource use: results from an observational study (ASSESS). COPD 2016; 13(5): 561-8. [PubMed] [Full Text]

70. Gruffydd-Jones K, Price D, et al. Changes in initial COPD treatment choice over time and factors influencing prescribing decisions in UK primary care: in UK primary care: a real-world, retrospective, observational. NPJ Prim Care Respir Med 2016; 26: 16002. [PubMed] [Full Text]

71. Westerik JA, Price DB, et al. Characteristics of patients making serious inhaler errors with a dry powder inhaler and association with asthma-related events in a primary care setting. J Asthma 2016; 53(3): 321-9. [PubMed] [Full Text]

72. Chrystyn H, Price DB, et al. Comparison of serious inhaler technique errors made by device-naïve patients using three different dry powder inhalers: a randomised, crossover, open-label study. BMC Pulm Med 2016; 16(1):12. [PubMed] [Full Text]

73. Price D, et al. Predicting frequent asthma exacerbations using blood eosinophil count and other patient data routinely available in clinical practice. J Asthma Allergy 2016; 9: 1-12. [PubMed] [Full Text]

74. Klimek L, Price D, et al. Safety evaluation of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) for allergic rhinitis. Expert Opin Drug Saf 2016; 15(1): 117-29. [PubMed] [Full Text]

75. Costa-Scharplatz M, Price D, et al. Cost-effectiveness of glycopyrronium bromide compared with tiotropium in patients with chronic obstructive pulmonary disease in Sweden. Appl Health Econ Health Policy 2015; 13(6): 637-45. [PubMed] [Full Text]

76. Price D, et al. The hidden burden of adult allergic rhinitis: UK healthcare resource utilisation survey. Clin Transl Allergy 2015; 5: 39. [PubMed] [Full Text]

77. Nwokoro C, Price D, et al. Parent-determined oral montelukast therapy for preschool wheeze with stratification for arachidonate 5-lipoxygenase (ALOX5) promoter genotype: a multicentre, randomised, placebo-controlled trial. Efficacy and Mechanism Evaluation 2015; 26. [PubMed] [Full Text]

78. Kerkhof M, Price DB, et al.; Respiratory Effectiveness Group. Predicting frequent COPD exacerbations using primary care data. Int J Chron Obstruct Pulmon Dis 2015; 10: 2439-50. [PubMed] [Full Text]

79. Price DB, et al. Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. Lancet Respir Med 2015; 3(11): 849–58. [PubMed] [Full Text]

80. Hellings PW, Price D, et al. A common language to assess allergic rhinitis control: results from a survey conducted during EAACI 2013 Congress. Clin Transl Allergy 2015; 5: 36. [PubMed] [Full Text]

81. Price D, et al. Time for a new language for asthma control: results from REALISE Asia. J Asthma Allergy 2015; 8: 93-103. [PubMed] [Full Text]

82. Brusselle G, Price D, et al. The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK. Int J Chron Obstruct Pulmon Dis 2015; 10: 2207-17. [PubMed] [Full Text]

83. Nathan RA, Price D, et al. Taking aim at asthma around the world: global results of the asthma insight and management survey in the Asia-Pacific region, Latin America, Europe, Canada, and the United States. J Allergy Clin Immunol Pract 2015; 3(5): 734-42.e5 [PubMed] [Full Text]

84. van Aalderen WM, Price D, et al. Small-particle inhaled corticosteroid as first-line or step-up controller therapy in childhood asthma. J Allergy Clin Immunol Pract 2015; 3(5): 721-31.e16. [PubMed] [Full Text]

85. Price D, et al. Establishing the relationship of inhaler satisfaction, treatment adherence, and patient outcomes: a prospective, real-world, cross-sectional survey of US adult asthma patients and physicians. World Allergy Organ J 2015; 8(1): 26. [PubMed] [Full Text]

86. Turner SW, Price D, et al. Initial step-up treatment changes in asthmatic children already prescribed inhaled corticosteroids: a historical cohort study. NPJ Prim Care Respir Med 2015; 25: 15041. [PubMed] [Full Text]

4

87. Devereux G, Price D, et al. Use of low-dose oral theophylline as an adjunct to inhaled corticosteroids in preventing exacerbations of chronic obstructive pulmonary disease: study protocol for a randomised controlled trial. Trials 2015; 16: 267. [PubMed] [Full Text]

88. Israel E, Price DB, et al. Increased dose of inhaled corticosteroid versus add-on long-acting β-agonist for step-up therapy in asthma. Ann Am Thorac Soc 2015; 12(6): 798-806. [PubMed] [Full Text]

89. Cazzola M, Price D, et al. Assessing the clinical value of fast onset and sustained duration of action of long-acting bronchodilators for COPD. Pulm Pharmacol Ther 2015; 31: 68-78. [PubMed] [Full Text]

90. Miravitlles M, Price D, et al. Comorbidities of patients in tiotropium clinical trials: comparison with observational studies of patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2015; 10: 549-64. [PubMed] [Full Text]

91. Papi A, Price D, et al. Efficacy of fluticasone propionate/formoterol fumarate in the treatment of asthma: a pooled analysis. Respir Med 2015; 109(2): 208-17. [PubMed] [Full Text]

92. Klimek L, Price D, et al. Effectiveness of MP29-02 for the treatment of allergic rhinitis in real-life: results from a noninterventional study. Allergy Asthma Proc 2015; 36(1): 40-7. [PubMed] [Full Text]

93. Price D, et al. Long-acting muscarinic antagonist use in adults with asthma: real-life prescribing and outcomes of add-on therapy with tiotropium bromide. J Asthma Allergy 2015; 8: 1-13. [PubMed] [Full Text]

94. Miravitlles M, Price D, et al. Observational study to characterise 24-hour COPD symptoms and their relationship with patient-reported outcomes: results from the ASSESS study. Respir Res 2014; 15: 122. [PubMed] [Full Text]

95. Park HS, Price D, et al. Physician-prescribed asthma treatment regimen does not differ between smoking and non-smoking patients with asthma in Seoul and Gyunggi province of Korea. Allergy Asthma Immunol Res 2014; 6: 30-6. [PubMed] [Full Text]

96. Price D, et al. Cost-effectiveness of the LABA/LAMA dual bronchodilator indacaterol/glycopyrronium in a Swedish healthcare setting. Respir Med 2014; 108(12): 1786-93. [PubMed] [Full Text]

97. Toumas-Shehata M, Price D, et al. Exploring the role of quantitative feedback in inhaler technique education: a cluster-randomised, two-arm, parallel-group, repeated-measures study. NPJ Prim Care Respir Med 2014; 13(24): 14071. [PubMed] [Full Text]

98. Postma DS, Price D, et al. Comparing the effectiveness of small-particle versus large-particle inhaled corticosteroid in COPD. Int J Chron Obstruct Pulmon Dis 2014; 9: 1163-86. [PubMed] [Full Text]

99. Nwokoro C, Price D, et al. Intermittent montelukast in children aged 10 months to 5 years with wheeze (WAIT trial): a multicentre, randomised, placebo-controlled trial. Lancet Respir Med 2014; 2(10): 796-803. [PubMed] [Full Text]

100. Martin RJ, Price D, et al. Cost-effectiveness of initiating extrafine- or standard size-particle inhaled corticosteroid for asthma in two health-care systems: a retrospective matched cohort study. NPJ Prim Care Respir Med 2014; 24: 14081. [PubMed] [Full Text]

101. Price D, et al. Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns. Int J Chron Obstruct Pulmon Dis 2014; 9: 889-904. [PubMed] [Full Text]

102. Ching SM, Price D, et al. Detection of airflow limitation using a handheld spirometer in a primary care setting. Respirology 2014; 19(5): 689-93. [PubMed] [Full Text]

103. Brockwell C, Price D, et al. Adjunctive treatment with oral AKL1, a botanical nutraceutical, in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2014; 9: 715-21. [PubMed] [Full Text]

104. Price D, et al. Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey. NPJ Prim Care Respir Med 2014; 12(24): 14009. [PubMed] [Full Text]

105. Price D, et al. Real-world characterization and differentiation of the Global Initiative for Chronic Obstructive Lung Disease strategy classification. Int J Chron Obstruct Pulom Dis 2014; 9: 551-61. [PubMed] [Full Text]

106. Price D, et al. Switching patients from other inhaled corticosteroid devices to the Easyhaler®: historical, matched-cohort study of real-life asthma patients. J Asthma Allergy 2014; 10(7): 31-51. [PubMed] [Full Text]

107. Jones R, Price D, et al.; Respiratory Effectiveness Group. Opportunities to diagnose chronic obstructive pulmonary disease in routine care in the UK: a retrospective study of a clinical cohort. Lancet Respir Med 2014; 2(4): 267-76. [PubMed] [Full Text]

108. Berger W, Price D, et al. Long-term, randomized safety study of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) in subjects with chronic rhinitis. J Allergy Clinical Immunol Pract 2014; 2(2): 179-85. [PubMed] [Full Text]

109. Price D, et al. Types, frequency and impact of asthma triggers on patients’ lives: a quantitative study in 5 European countries. J Asthma 2014; 51(2): 127-35. [PubMed] [Full Text]

110. Price D, et al. A new therapy (MP29-02) is effective for the long-term treatment of chronic rhinitis. J Investig Allergol Clin Immunol 2013; 23(7): 495-503. [PubMed] [Full Text]

111. Price D, et al. Clinical and cost effectiveness of switching asthma patients from fluticasone-salmeterol to extra-fine particle beclometasone-formoterol: a retrospective matched observational study of real-world patients. Prim Care Respir J 2013; 22(4): 439-48. [PubMed] [Full Text]

112. Price D, et al. Impact of night-time symptoms in COPD: a real-world study in five European countries. Int J Chron Obstruc Pulmon Dis 2013; 8: 595-603. [PubMed] [Full Text]

113. Price D, et al. Using fractional exhaled nitric oxide (FeNO) to diagnose steroid-responsive disease and guide asthma management in routine care. Clin Transl Allergy 2013; 3(1): 37. [PubMed] [Full Text]

114. Price D, et al. Real-life comparison of beclometasone dipropionate as an extrafine- or larger-particle formulation for asthma. Respir Med 2013; 107(7): 987-1000. [PubMed] [Full Text]

115. Colice G, Price D, et al. Asthma outcomes and costs of therapy with extrafine beclomethasone and fluticasone. J Allergy Clin Immunol 2013; 132(1): 45-54. [PubMed] [Full Text]

116. Price D, et al. A UK-based cost-utility analysis of indacaterol, a once-daily maintenance bronchodilator for patients with COPD, using real world evidence on resource use. Appl Health Econ Health Policy 2013; 11(3): 259-74. [PubMed] [Full Text]

117. Price D, et al. Characteristics of patients preferring once-daily controller therapy for asthma and COPD: a retrospective cohort study. Prim Care Respir J 2013; 22(2): 161-8. [PubMed] [Full Text]

5

118. Bruton A, Price D, et al. The BREATHE study: Breathing REtraining for Asthma - trial of home exercises. A protocol summary of a randomised controlled trial. Prim Care Respir J 2013; 22: PS1-7. [PubMed] [Full Text]

119. Meltzer E, Price D, et al. Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysis. Int Arch Allergy Immunol 2013; 161(4): 369-77. [PubMed] [Full Text]

120. Braido F, Price D, et al. InternationaL cross-sectIonAl and longItudinal assessment on aSthma cONtrol in European adult patients--the LIAISON study protocol. BMC Pulm Med 2013; 13: 18. [PubMed] [Full Text]

121. Price D, et al. Effect of montelukast for treatment of asthma in cigarette smokers. J Allergy Clin Immunol 2013; 131(3): 763-71. [PubMed] [Full Text]

122. Lenney W, Price D, et al. MASCOT Study Group. Management of Asthma in School age Children On Therapy (MASCOT): a randomised, double-blind, placebo-controlled, parallel study of efficacy and safety. Health Technol Assess 2013; 17(4): 1-218. [PubMed] [Full Text]

123. Price D, et al. Effect of inhaled corticosteroid therapy step-down and dosing regimen on measures of asthma control. J Allergy Ther 2013; 4(1): 126. [Full Text]

124. Smith JR, Price DB, et al. The at-risk registers in severe asthma (ARRISA) study: a cluster-randomised controlled trial examining effectiveness and costs in primary care. Thorax 2012; 67(12): 1052-60. [PubMed] [Full Text]

125. Carr W, Price D, et al. Comparison of intranasal azelastine to intranasal fluticasone propionate for symptom control in moderate-to-severe seasonal allergic rhinitis. Allergy Asthma Proc 2012; 33(6): 450-8. [PubMed] [Full Text]

126. Pinnock H, Price DB, et al. Clinical implications of the Royal College of Physicians three questions in routine asthma care: a real-life validation study. Prim Care Respir J 2010; 21(3): 288-94. [PubMed] [Full Text]

127. Malhotra S, Price DB, et al. The challenge of recruiting in primary care for a trial of telemonitoring in asthma: an observational study. Pragmat Obs Res 2012; 3(1): 51-5. [PubMed] [Full Text]

128. Meltzer EO, Price D, et al. MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) in the treatment of seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial of efficacy and safety. Allergy Asthma Proc 2012; 33(4): 324-32. [PubMed] [Full Text]

129. Price D, et al. Effectiveness of same versus mixed asthma inhaler devices: a retrospective observational study in primary care. Allergy Asthma Immunol Res 2012; 4(4): 184-91. [PubMed] [Full Text]

130. Carr W, Price D, et al. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. J Allergy Clin Immunol 2012; 129(5): 1282-9. [PubMed] [Full Text]

131. Ryan D, Price D, et al. Clinical and cost effectiveness of mobile phone supported self monitoring of asthma: multicentre randomised controlled trial. BMJ 2012; 344: e1756. [PubMed] [Full Text]

132. Bousquet J, Price D, et al.; Global Allergy and Asthma European Network (GA²LEN). Inhaled corticosteroid/long-acting β₂-agonist combination therapy for asthma: attitudes of specialists in Europe. Int Arch Allergy Immunol 2012; 157(3): 303-10. [PubMed] [Full Text]

133. Thomas M, Price D, et al. Physicians’ attitudes towards combination therapy with inhaled corticosteroids and long-acting ß2-agonists: an observational study in UK specialist care. Pragmat Obs Res 2011; 2: 25-31. [PubMed] [Full Text]

134. Price D, et al. Cost-utility analysis of indacaterol in Germany: a once-daily maintenance bronchodilator for patients with COPD. Respir Med 2011; 105(11): 1635-47. [PubMed] [Full Text]

135. Barnes N, Price D, et al. Asthma control with extrafine-particle hydrofluoroalkane-beclometasone vs. large-particle chlorofluorocarbon-beclometasone: a real-world observational study. Clin Exp Allergy 2011; 41(11): 1521-32. [PubMed] [Full Text]

136. Price D, et al. Device type and real-world effectiveness of asthma combination therapy: An observational study. Respir Med 2011; 105(10): 1457-66. [PubMed] [Full Text]

137. Kielmann T, Price D, et al. From awareness to involvement? A qualitative study of respiratory patients’ awareness of health service change. Health Expect 2011; 14(3): 321-33. [PubMed] [Full Text]

138. Price D, et al. A pragmatic single-blind randomised controlled trial and economic evaluation of the use of leukotriene receptor antagonists in primary care at steps 2 and 3 of the national asthma guidelines (ELEVATE study). Health Technol Assess 2011; 15(21): 131-2. [PubMed] [Full Text]

139. Price D, et al. Leukotriene antagonists as first-line or add-on asthma-controller therapy. N Engl J Med 2011; 364(18): 1695-707. [PubMed] [Full Text]

140. Price D, et al. Effectiveness of inhaler types for real-world asthma management: retrospective observational study using the GPRD. J Asthma Allergy 2011; 4: 37-47. [PubMed] [Full Text]

141. Zhang Q, Price D, et al. Suboptimal persistence with inhaled corticosteroid monotherapy among children with persistent asthma in the UK. Prim Care Respir J 2011; 20(1): 408. [PubMed] [Full Text]

142. Chavannes N, Price D, et al. UNLOCK: Uncovering and Noting Long-term Outcomes in COPD to enhance Knowledge. Prim Care Respir J 2010; 19(4): 408. [PubMed] [Full Text]

143. Price D, et al. Prescribing practices and asthma control with hydrofluoroalkane-beclomethasone and fluticasone: a real-world observational study. J Allergy Clin Immunol 2010; 126(3): 511-8.e10. [PubMed] [Full Text]

144. Price D, et al. Observational study comparing intranasal mometasone furoate with oral antihistamines for rhinitis and asthma. Prim Care Respir J 2010; 19(3): 266-73. [PubMed] [Full Text]

145. Kemp L, Price D, et al. Cost-effectiveness analysis of corticosteroid inhaler devices in primary care asthma management: A real world observational study. Clinicoecon Outcome Res 2010; 2: 75-85. [PubMed] [Full Text]

146. Wilson EC, Price D, et al. Cost effectiveness of leukotriene receptor antagonists versus long-acting beta-2 agonists as add-on therapy to inhaled corticosteroids for asthma: a pragmatic trial. Pharmacoeconomics 2010; 28(7): 597-608. [PubMed] [Full Text]

147. Wilson EC, Price D, et al. Cost effectiveness of leukotriene receptor antagonists versus inhaled corticosteroids for initial asthma controller therapy: a pragmatic trial. Pharmacoeconomics 2010; 28(7): 585-95. [PubMed] [Full Text]

148. Faulkner J, Price D, et al. The feasibility of recruiting patients with early COPD to a pilot trial assessing the effects of a physical activity intervention. Prim Care Respir J 2010; 19(2): 124-30. [PubMed] [Full Text]

6

149. Kielmann T, Price D, et al. From support to boundary: A qualitative study of the border between self-care and professional care. Patient Educ Couns 2010; 79(1): 55-61. [PubMed] [Full Text]

150. Doyle S, Price D, et al. What happens to patients who have their asthma device switched without their consent?. Prim Care Respir J 2010; 19(2): 131-9. [PubMed] [Full Text]

151. Price D, et al. Improved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler: a randomized open-label study. BMC Pulm Med 2010; 10: 1. [PubMed] [Full Text]

152. Jones RC, Price D, et al. Derivation and validation of a composite index of severity in chronic obstructive pulmonary disease: the DOSE Index. Am J Respir Crit Care Med 2009; 180(12): 1189-95. [PubMed] [Full Text]

153. Clatworthy J, Price D, et al. The value of self-report assessment of adherence, rhinitis and smoking in relation to asthma control. Prim Care Respir J 2009; 18(4): 300-5. [PubMed] [Full Text]

154. Ryan D, Price D, et al. The CYMPLA trial. Mobile phone-based structured intervention to achieve asthma control in patients with uncontrolled persistent asthma: a pragmatic randomised controlled trial. Prim Care Respir J 2009; 18(4): 343-5. [PubMed] [Full Text]

155. Taegtmeyer AB, Price DB, et al. Predictors of asthma control in everyday clinical practice in Switzerland. Curr Med Res Opin 2009; 25(10): 2549-55. [PubMed] [Full Text]

156. Wilson E, Price D, et al. Befriending carers of people with dementia: a cost utility analysis. Int J Geriatr Psychiatry 2009; 24(6): 610-23. [PubMed] [Full Text]

157. Winchester CC, Price D, et al. Antibiotic prescribing and outcomes of lower respiratory tract infection in UK primary care. Chest 2009; 135(5): 1163-72. [PubMed] [Full Text]

158. Thomas M, Price D, et al. The Asthma Control TestTM (ACT) as a predictor of GINA guideline-defined asthma control: analysis of a multinational cross-sectional survey. Prim Care Resp J 2009; 18(1): 41-9. [PubMed] [Full Text]

159. Price D, et al. An economic evaluation of NIOX MINO airway inflammation monitor in the United Kingdom. Allergy 2009; 64(3): 431-8. [PubMed] [Full Text]

160. Van Cauwenberge P, Price D, et al. The current burden of allergic rhinitis amongst primary care practitioners and its impact on patient management. Prim Care Respir J 2009; 18(1): 27-33. [PubMed] [Full Text]

161. Thomas M, Price D, et al. Breathing exercises for asthma: a randomised controlled trial. Thorax 2009; 64(1): 55-61. [PubMed] [Full Text]

162. Thomas M, Price D, et al. Inhaled corticosteroids for asthma: impact of practice level device switching on asthma control. BMC Pul Med 2009; 9: 1. [PubMed] [Full Text]

163. Thomas M, Price D, et al. High-dose inhaled corticosteroids versus add-on long-acting beta-agonists in asthma: an observational study. J Allergy Clin Immunol 2009; 123(1):116-21.e10. [PubMed] [Full Text]

164. Turner SW, Price D, et al. Prescribing trends in asthma: a longitudinal observational study. Arch Dis Child 2009; 94(1): 16-22. [PubMed] [Full Text]

165. Green RJ, Price D, et al. Perceptions, impact and management of asthma in South Africa: a patient questionnaire study. Prim Care Respir J 2008; 17(4): 212-6. [PubMed] [Full Text]

166. Griffin J, Price D, et al. Comparison of tiotropium bromide and combined ipratropium/salbutamol for the treatment of COPD: a UK General Practice Research Database 12-month follow-up study. Prim Care Respir J 2008; 17(2): 104-10. [PubMed] [Full Text]

167. Charlesworth G, Price D, et al. Befriending carers of people with dementia: randomised controlled trial. BMJ 2008; 336(7656): 1295-7. [PubMed] [Full Text]

168. Harnest U, Price D, et al. Comparison of mometasone furoate dry powder inhaler and fluticasone propionate dry powder inhaler in patients with moderate to severe persistent asthma requiring high-dose inhaled corticosteroid therapy: findings from a noninferiority trial. J Asthma 2008; 45(3): 215-20. [PubMed] [Full Text]

169. Cleland JA, Price D, et al. An exploratory, pragmatic, cluster randomised trial of practice nurse training in the use of asthma action plans. Prim Care Respir J 2007; 16(5): 311-8. [PubMed] [Full Text]

170. Green RJ, Price D, et al. Concerns of patients with allergic rhinitis: the Allergic Rhinitis Care Programme in South Africa. Prim Care Respir J 2007; 16(5): 299-303. [PubMed] [Full Text]

171. Price D, et al. Cost-effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy. Allergy 2007; 62(10): 1189-98. [PubMed] [Full Text]

172. Price DB, et al. Salmeterol/fluticasone stable-dose treatment compared with formoterol/budesonide adjustable maintenance dosing: impact on health-related quality of life. Respir Res 2007; 8: 46. [PubMed] [Full Text]

173. Freeman D, Price D, et al. Efficacy and safety of tiotropium in COPD patients in primary care--the SPiRiva Usual CarE (SPRUCE) study. Respir Res 2007; 8: 45. [PubMed] [Full Text]

174. Van Aalderen WM, Price D, et al. Beclometasone dipropionate extrafine aerosol versus fluticasone propionate in children with asthma. Respir Med 2007; 101(7): 1585-93. [PubMed] [Full Text]

175. Iversen L, Price D, et al. Do people self-reporting information about chronic respiratory disease have corroborative evidence in their general practice medical records? A study of intermethod reliability. Prim Care Respir J 2007; 16(3): 162-8. [PubMed] [Full Text]

176. Pinnock H, Price D, et al. Understanding the potential role of mobile phone based monitoring on asthma self-management: qualitative study. Clin Exp Allergy 2007; 37(5): 794-802. [PubMed] [Full Text]

177. Doull I, Price D, et al. Cost-effectiveness of salmeterol xinafoate/fluticasone propionate combination inhaler in chronic asthma. Curr Med Res Opin 2007; 23(5): 1147-59. [PubMed] [Full Text]

178. Foster J, Price D, et al. Practice development plans to improve the primary care management of acute asthma: randomised controlled trial. BMC Fam Prac 2007; 8: 23. [PubMed] [Full Text]

179. Haughney J, Price D, et al. The use of a modification of the Patient Enablement Instrument in asthma. Prim Care Respir J 2007; 16(2): 89-92. [PubMed] [Full Text]

180. Tinkelman D, Price D, et al. COPD screening efforts in primary care: what is the yield?. Prim Care Respir J 2007; 16(1): 41-8. [PubMed] [Full Text]

7

181. Lloyd A, Price D, et al. The impact of asthma exacerbations on health-related quality of life in moderate to severe asthma patients in the UK. Prim Care Respir J 2007; 16(1): 22-7. [PubMed] [Full Text]

182. Moffat M, Price D, et al. Poor communication may impair optimal asthma care: a qualitative study. Fam Pract 2007; 24(1): 65-70. [PubMed] [Full Text]

183. Robertson CF, Price D, et al. Short-course montelukast for intermittent asthma in children: a randomized controlled trial. Am J Respir Crit Care Med 2007; 175(4): 323-9. [PubMed] [Full Text]

184. Sheikh A, Price D, et al. Standardized training for healthcare professionals and its impact on patients with perennial rhinitis: a multi-centre randomized controlled trial. Clin Exp Allergy 2007; 37(1): 90-9. [PubMed] [Full Text]

185. Zhang Q, Price D, et al. Treatment and outcomes in patients with asthma and allergic rhinitis in the United Kingdom. Inter Arch of Allergy and Imm 2007; 142(4): 318-28. [PubMed] [Full Text]

186. Pearson M, Price D, et al. Diagnosis of airway obstruction in primary care in the UK: the CADRE (COPD and Asthma Diagnostic/management REassessment) programme 1997-2001. Inter J Chron Obstruct Pulmon Dis 2006; 1(4): 435-43. [PubMed]

187. Thomas M, Price D, et al. High-dose inhaled corticosteroid use in childhood asthma: an observational study of GP prescribing. Br J Gen Pract 2006; 56(531): 788-90. [PubMed] [Full Text]

188. Pinnock H, Price D, et al. Professional and patient attitudes to using mobile phone technology to monitor asthma: questionnaire survey. Prim Care Respir J 2006; 15(4): 237-45. [PubMed] [Full Text]

189. Price DB, et al. Scoring system and clinical application of COPD diagnostic questionnaires. Chest 2006; 129(6): 1531-9. [PubMed] [Full Text]

190. Cleland JA, Price DB, et al. A pragmatic, three-arm randomised controlled trial of spiritual healing for asthma in primary care. Br J Gen Pract 2006; 56(527): 444-9. [PubMed] [Full Text]

191. Price DB, et al. Effect of montelukast on lung function in asthma patients with allergic rhinitis: analysis from the COMPACT trial. Allergy 2006; 61(6): 737-42. [PubMed] [Full Text]

192. Thomas M, Price D, et al. High-dose inhaled corticosteroids and add-on therapy use in adults with asthma in the UK in 2003: an observational study. Prim Care Respir J 2006; 15(3): 166-72. [PubMed] [Full Text]

193. Moffat M, Price D, et al. Sub-optimal patient and physician communication in primary care consultations: its relation to severe and difficult asthma. Prim Care Respir J 2006; 15(3): 159-65. [PubMed] [Full Text]

194. Moffat MA, Price D, et al. Can a GP be a generalist and a specialist? Stakeholders views on a respiratory General Practitioner with a special interest service in the UK. BMC Health Service Res 2006; 6: 62. [PubMed] [Full Text]

195. Adams R, Price D, et al. Exacerbations of chronic obstructive pulmonary disease: A patients’ perspective. Prim Care Respir J 2006; 15(2): 102-9. [PubMed] [Full Text]

196. Tinkelman DG, Price DB, et al. Symptom-based questionnaire for differentiating COPD and asthma. Respiration 2006; 73(3): 296-305. [PubMed] [Full Text]

197. Price DB, et al. Symptom-based questionnaire for identifying COPD in smokers. Respiration 2006; 73(3): 285-95. [PubMed] [Full Text]

198. Tinkelman D, Price D, et al. Misdiagnosis of COPD and asthma in primary care patients 40 years of age and over. J Asthma 2006; 43(1): 75-80. [PubMed] [Full Text]

199. Sinclair H, Price D, et al. Community pharmacy provision of allergic rhinitis treatments: a longitudinal study of patient reported outcome. Int J Pharm Pract 2005; 13(4): 249-56. [Full Text]

200. Vogelmeier C, Price D, et al. Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option?. Eur Respir J 2005; 26(5): 819-28. [PubMed] [Full Text]

201. Iversen L, Price DB, et al. Is living in a rural area good for your respiratory health? Results from a cross-sectional study in Scotland. Chest 2005; 128(4): 2059-67. [PubMed] [Full Text]

202. Freeman D, Price D, et al. Questions for COPD diagnostic screening in a primary care setting. Respir Med 2005; 99(10): 1311-8. [PubMed] [Full Text]

203. Ryan D, Price D, et al. Mobile phone technology in the management of asthma. J Telemed Telecare 2005; 11(Suppl 1): 43-6. [PubMed] [Full Text]

204. Pinnock H, Price D, et al. General practitioners with a special interest in respiratory medicine: national survey of UK primary care organisations. BMC Health Serv Res 2005; 5: 40. [PubMed] [Full Text]

205. Ruigomez A, Price D, et al. Gastroesophageal reflux disease and asthma: a longitudinal study in UK general practice. Chest 2005; 128(1): 85-93. [PubMed] [Full Text]

206. Thomas M, Price D, et al. The prevalence of dysfunctional breathing in adults in the community with and without asthma. Prim Care Respir J 2005; 14(2): 78-82. [PubMed] [Full Text]

207. Price D, et al. Effect of a concomitant diagnosis of allergic rhinitis on asthma-related health care use by adults. Clin Exp Allergy 2005; 35(3): 282-7. [PubMed] [Full Text]

208. Pinnock H, Price D, et al. Cost-effectiveness of telephone or surgery asthma reviews: economic analysis of a randomised controlled trial. Br J Gen Pract 2005; 55(511): 119-24. [PubMed] [Full Text]

209. Thomas M, Price D, et al. Asthma-related health care resource use among asthmatic children with and without concomitant allergic rhinitis. Pediatrics 2005; 115(1): 129-34. [PubMed] [Full Text]

210. Barnes N, Price D, et al. The national montelukast survey. J Allergy Clin Immunol 2005; 115(1): 47-54. [PubMed] [Full Text] 211. Price D, et al. An economic evaluation of adjustable and fixed dosing with budesonide/formoterol via a single inhaler in

asthma patients: the ASSURE study. Curr Med Res Opin 2004; 20(10): 1671-9. [PubMed] [Full Text] 212. Ind PW, Price D, et al. Adjustable and fixed dosing with budesonide/ formoterol via a single inhaler in asthma patients: the

ASSURE study. Respir Med 2004; 98(5): 464-75. [PubMed] [Full Text] 213. Levy ML, Price D, et al. Inadequacies in UK primary care allergy services: national survey of current provisions and

perceptions of need. Clin Exp Allergy 2004; 34(4): 518-9. [PubMed] [Full Text] 214. Pinnock H, Price D, et al. A pilot study to assess the feasibility and acceptability of undertaking acute asthma professional

development in three different UK primary care settings. Prim Care Respir J 2003; 12: 7–11. [Full Text]

8

215. Pinnock H, Price D, et al. Accessibility, acceptability, and effectiveness in primary care of routine telephone review of asthma: pragmatic, randomised controlled trial. BMJ 2003; 326(7387): 477-9. [PubMed] [Full Text]

216. Price D, et al. Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Thorax 2003; 58(3): 211-6. [PubMed] [Full Text]

217. Thomas M, Price D, et al. Breathing retraining for dysfunctional breathing in asthma: a randomised controlled trial. Thorax 2003; 58(2): 110-5. [PubMed] [Full Text]

218. Price DB, et al. Community-acquired pneumonia mortality: a potential link to antibiotic prescribing trends in general practice. Respir Med 2004; 98(1): 17-24. [PubMed] [Full Text]

219. Price D, et al. Improvement of asthma control with a breath-actuated pressurised metred dose inhaler (BAI): a prescribing claims study of 5556 patients using a traditional pressurised metred dose inhaler (MDI) or a breath-actuated device. Respir Med 2003; 97(1): 12-9. [PubMed] [Full Text]

220. Moffat M, Price D, et al. General practitioners’ understanding of severe and difficult asthma: a qualitative study. Prim Care Respir J 2002; 11(3): 99-102. [Full Text]

221. Price D, et al. Early asthma control and maintenance with eformoterol following reduction of inhaled corticosteroid dose. Thorax 2002; 57(9): 791-8. [PubMed] [Full Text]

222. Price D, et al. The cost effectiveness of chlorofluorocarbon-free beclomethasone dipropionate in the treatment of chronic asthma: a cost model based on a 1-year pragmatic, randomised clinical study. Pharmacoeconomics 2002; 20(10): 653-64. [PubMed] [Full Text]

223. Juniper EF, Price DB, et al. Clinically important improvements in asthma-specific quality of life, but no difference in conventional clinical indexes in patients changed from conventional beclomethasone dipropionate to approximately half the dose of extrafine beclomethasone dipropionate. Chest 2002; 121(6): 1824-32. [PubMed] [Full Text]

224. Price D, et al. The burden of paediatric asthma is higher than health professionals think: results from the Asthma In Real Life (AIR) study. Prim Care Respir J 2002; 11(2): 30-3. [Full Text]

225. Price DB, Freeman D. The BREATH (Breathlessness Research, Expectations and Treatment hopes) study: findings of a pilot study in four countries. Prim Care Respir J 2002; 11(Suppl 1): s12-s14.

226. Price DB, et al. Use of Montelukast in tapering inhaled corticosteroid therapy: an open-label, 48-week trial. Curr Ther Res 2001; 62(11): 743-55. [Full Text]

227. Price DB, et al. Changes in asthma drug therapy costs for patients receiving chronic montelukast therapy in the U.K. Respir Med 2001; 95(1): 83-9. [PubMed] [Full Text]

228. Price D, et al. Asthma and analgesics: A patient awareness study. Asthma J 2000; 5: 191. 229. Price D, Wolfe S. Delivery of asthma care: patients' use of and views on healthcare services, as determined from a nationwide

interview survey. Asthma J 2000; 5: 141-4. 230. Price D, et al. The AIR study: asthma in real life. Asthma J 1999; 4: 74-8. 231. Price D, et al. Handling and acceptability of the Easi-Breathe device compared with a conventional metered dose inhaler by

patients and practice nurses. Int J Clin Pract 1999; 53(1): 31-6. [PubMed] 232. Price D, et al. Concerns and misconceptions regarding steroid therapy in asthma: findings and impact of a public meeting.

Asthma Gen Pract 1998; 6(3): 43-4. [Full Text] 233. Price DB, et al. Salmeterol xinafoate: an analysis of outcomes and cost-effectiveness using a primary care database. Respir

Med 1998; 92(11): 1302-4. [PubMed] [Full Text] 234. Price DB, Appleby JL. Fluticasone propionate: an audit of outcomes and cost-effectiveness in primary care. Respir Med 1998;

92(2): 351-3. [PubMed] [Full Text] 235. Gruffydd-Jones K, Price DB, et al. A within-patient comparison of subcutaneous and oral sumatriptan in the acute treatment of

migraine in general practice. Cephalalgia 1997; 17(1): 31-6. [PubMed] [Full Text]

Guideline Participation: Final Publications 1. Brożek JL, Price D, et al. Allergic rhinitis and its impact on asthma (ARIA) guidelines - 2016 revision. J Allergy Clin

Immunol 2017; 140(4): 950-958. [PubMed] [Full Text] 2. Sin DD, Price D, et al. What is asthma−COPD overlap syndrome? Towards a consensus definition from a round table

discussion. Eur Respir J 2016; 48(3): 664-73. [PubMed] [Full Text] 3. Bousquet J, Price D, et al.; MASK study group. MACVIA clinical decision algorithm in adolescents and adults with allergic

rhinitis. J Allergy Clin Immunol 2016; 138(2): 367-74. [PubMed] [Full Text] 4. Bousquet J, Price D, et al. MACVIA-ARIA Sentinel NetworK for allergic rhinitis (MASK-rhinitis): the new generation guideline

implementation. Allergy 2015; 70(11): 1372-92. [PubMed] [Full Text] 5. Bousquet J, Price D, et al. Integrated care pathways for airway diseases (AIRWAYS-ICPs). Eur Respir J 2014; 44(2): 304-32.

[PubMed] [Full Text] 6. Price D, et al. A guide to performing quality assured diagnostic spirometry. Education for Health 2013. [Full Text] 7. Price D, et al. The primary care management of asthma in real-life settings. Guidelines in practice 2013; 49: 1-5. [Link] 8. Griffiths C, Price D, et al. Delivery/Organisation of Care. Brown K, Thompson L, Twaddle S (eds). British guideline on the

management of asthma: a national clinical guideline. : British Thoracic Society and Scottish Intercollegiate Guidelines Network; 2012. pp. 94-7. [Full Text].

9. Bousquet J, Price D, et al. Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs. J Allergy Clin Immunol 2012; 130(5): 1049-62. [PubMed] [Full Text]

10. WHO Collaborating Center for Asthma and Rhinitis, Bousquet J, Price D, et al. Severe chronic allergic (and related) diseases: a uniform approach – a MeDALL–GA²LEN–ARIA position paper. Int Arch Allergy Immunol 2012; 158(3): 216-31. [PubMed] [Full Text]

11. Fokkens WJ, Price D, et al. European position paper on rhinosinusitis and nasal polyps 2012. Rhinology 2012; 50(Suppl 23): 1-298. [PubMed] [Full Text]

9

12. Fokkens WJ, Price D, et al. EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology 2012; 50(1): 1-12. [PubMed]

13. Bousquet J, Price D, et al.; in collaboration with the WHO Collaborating Center of Asthma and Rhinitis (Montpellier). Development and implementation of guidelines in allergic rhinitis – an ARIA-GA²LEN paper. Allergy 2010; 65(10): 1212-21. [PubMed] [Full Text]

14. Brozek JL, et al.; Global Allergy and Asthma European Network; Grading of Recommendations Assessment, Development and Evaluation Working Group. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol 2010; 126(3): 466-76. [PubMed] [Full Text]

15. Pavord I, Price D. Utilising budesonide/formoterol in a single inhaler for relief and maintenance in asthma: BTS/SIGN recommendations. Prescriber Suppl 2010: 1-8.

16. Jones PW, et al. Development and first validation of the COPD Assessment Test. Eur Respir J 2009; 34(3): 648-54. [PubMed] [Full Text]

17. Bousquet J, et al.; Extended Global Allergy and Asthma European Network, World Allergy Organization and Allergic Rhinitis and its Impact on Asthma Study Group. Unmet needs in severe chronic upper airway disease (SCUAD). J Allergy Clin Immunol 2009; 124(3): 428-33. [PubMed] [Full Text]

18. Thomas M, Price D, et al. EPOS Primary Care Guidelines: European position paper on the primary care diagnosis and management of rhinosinusitis and nasal polyps 2007: a summary. Prim Care Respir J 2008; 17(2): 79-89. [PubMed] [Full Text]

19. Griffiths C, Price D, et al. Delivery/Organisation of Care. Johnston SL, Mitchell DM (eds). British guideline on the management of asthma: a national clinical guideline. : British Thoracic Society and Scottish Intercollegiate Guidelines Network; 2008. pp. 94-7. [Full Text]. Published in Thorax 2008; 63(Suppl 4): iv1-121. [PubMed] [Full Text]

20. Bousquet J, Price D, et al.; World Health Organization; GA2LEN; AllerGen. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA²LEN and AllerGen). Allergy 2008; 63(Suppl 86): 8-160. [PubMed] [Full Text]

21. Thomas M, Price D, et al. Consensus guideline on the use of inhaler devices in asthma, Guidelines Suppl 2007 ed. Buckinghamshire, England: Medendium Group Publishing Limited; 2007.

22. Fokkens W, et al.; European Position Paper on Rhinosinusitis and Nasal Polyps group. European position paper on rhinosinusitis and nasal polyps 2007. Rhinology 2007; 45(Suppl 20): 1-139. [PubMed] [Full Text]

23. Passalacqua G, Durham SR; in cooperation with the Global Allergy and Asthma European Network (GA2LEN). Allergic rhinitis and its impact on asthma update: allergen immunotherapy. J Allergy Clin Immunol 2007; 119(4): 881-91. [PubMed] [Full Text]

24. Bousquet J, Price D, et al.; GA²LEN. Pharmacologic and anti-IgE treatment of allergic rhinitis ARIA update (in collaboration with GA²LEN). Allergy 2006; 61(9): 1086-96. [PubMed] [Full Text]

25. Price D, et al. International Primary Care Respiratory Group (IPCRG) guidelines: management of allergic rhinitis. Prim Care Respir J 2006; 15(1): 58-70. [PubMed] [Full Text]

26. Levy ML, Price DB, et al. International Primary Care Respiratory Group (IPCRG) guidelines: diagnosis of respiratory diseases in primary care. Prim Care Respir J 2006; 15(1): 20-34. [PubMed] [Full Text]

27. Levy M, Price D, et al. Diagnosis. Grouse L, DeWeerdt S (eds). The International Primary Care Airways Group (IPAG). Diagnosis and management handbook. Chronic airways diseases: a guide for primary care physicians. : MCR Vision Inc; 2005. pp. 1-13. [Full Text]

28. Price DB, Thomas MD; Asthma UK. Where next in clinical asthma research? An Asthma UK consultation on clinical asthma research strategy. Asthma UK 2004.

29. Price D; Members of the Workshops. ARIA in the pharmacy: management of allergic rhinitis symptoms in the pharmacy. Allergic rhinitis and its impact on asthma. Allergy 2004; 59(4): 373-87. [PubMed] [Full Text]

30. Bousquet J, Price D, et al.; European Academy of Allergy and Clinical Immunology (EAACI); Allergic Rhinitis and its Impact on Asthma (ARIA). Requirements for medications commonly used in the treatment of allergic rhinitis. Allergy 2003; 58: 192-7. [PubMed] [Full Text]

31. Price D; British Thoracic Society; Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma: a national clinical guideline. Thorax 2003; 58(Suppl 1): i1-94. [PubMed] [Full Text]

32. Bousquet J, Price D, et al.; and the Workshop Expert Panel. Allergic Rhinitis and its Impact on Asthma (ARIA): in collaboration with the World Health Organization. Allergy 2002; 57(9): 841-55. [PubMed] [Full Text]

33. Scottish Intercollegiate Guidelines Network (SIGN). Community management of lower respiratory tract infection in adults: a national clinical guideline. Edinburgh; 2002.

34. Price D; for the British Thoracic Society Air Travel Guidelines Working Party. Managing passengers with respiratory disease planning air travel: British Thoracic Society recommendations. Summary for primary care. Thorax 2002; 57(4):1-2. [PubMed] [Full Text]

35. Bousquet J, Price D, et al.; Aria Workshop Group; in collaboration with the World Health Organization. Allergic rhinitis and its impact on asthma. 108 2001; 108(Suppl 5): S147-333. [PubMed] [Full Text]

Reviews and Discussion

1. Vandenplas O, Price D, et al. Impact of rhinitis on work productivity: a systematic review. J Allergy Clin Immunol Pract 2017. 2. Sonnappa S, Price DB, et al. Extrafine versus fine inhaled corticosteroids in relation to asthma control: a systematic review

and meta-analysis of observational real-life studies. J Allergy Clin Immunol Pract 2017. 3. Price D, et al. Asthma referrals: a key component of asthma management that needs to be addressed. J Asthma

Allergy 2017; 10: 209-223. [PubMed] [Full Text] 4. Costello RW, Price D, et al. Effective deployment of technology-supported management of chronic respiratory conditions: a

call for stakeholder engagement. Pragmat Obs Res 2017; 8: 119-128. [PubMed] [Full Text] 5. Price D, et al. Dual bronchodilation in COPD: lung function and patient-reported outcomes – a review. Int J Chron Obstruct

Pulmon Dis 2017; 12: 141-168. [PubMed] [Full Text]

10

6. Bousquet J, Price D, et al. Building bridges for innovation in ageing: synergies between action groups of the EIP on AHA. J Nutr Health Aging 2017; 21(1): 92–104. [PubMed] [Full Text]

7. Bousquet J, Price D, et al. ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle. Clin Transl Allergy 2016; 6: 47. [PubMed] [Full Text]

8. Vrijens B, Price D, et al. What we mean when we talk about adherence in respiratory medicine. J Allergy Clin Immunol Pract 2016; 4(5): 802-12. [PubMed] [Full Text]

9. Braido F, Price D, et al.; on behalf of the Respiratory Effectiveness Group. “Trying, but failing” — the role of inhaler technique and mode of delivery in respiratory medication adherence. J Allergy Clin Immunol Pract 2016; 4(5): 823-32. [PubMed] [Full Text]

10. Bousquet J, Price D, et al. Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5). Clin Transl Allergy 2016; 6: 29. [PubMed] [Full Text]

11. Djukanovic R, Price D, et al. IgE-mediated asthma: new revelations and future insights. Respir Med 2016; 112: 128-9. [PubMed] [Full Text]

12. Klimek L, Price D, et al. Effectiveness of allergic rhinitis treatments in real-life with a focus on MP-AzeFlu. Expert Rev Clin Pharmacol 2016; 9(5): 705-14. [PubMed] [Full Text]

13. Lenney W, Price D, et al. Lessons learnt from a primary care asthma improvement project. NPJ Prim Care Respir Med 2016; 26: 15075. [PubMed] [Full Text]

14. D'Urzo T, Price D, et al. Dual bronchodilator therapy with aclidinium bromide/formoterol fumarate for chronic obstructive pulmonary disease. Expert Rev Respir Med 2015; 9(5): 519-32. [PubMed] [Full Text]

15. Price D, et al. Current controversies and challenges in allergic rhinitis management. Expert Rev Clin Immunol 2015; 11(11): 1205-17. [PubMed] [Full Text]

16. D'Urzo A, Price D, et al. A re-evaluation of the role of inhaled corticosteroids in the management of patients with chronic obstructive pulmonary disease. Expert Opin Pharmacother 2015; 16(12): 1845-60. [PubMed] [Full Text]

17. Brand PL, Price D, et al.; ERS Task Force Monitoring Asthma in Children. Monitoring asthma in childhood: symptoms, exacerbations and quality of life. Eur Respir Rev 2015; 24(136): 187-93. [PubMed] [Full Text]

18. Pijnenburg MW, Price D, et al. Monitoring asthma in children. Eur Respir J 2015; 45(4): 906-25. [PubMed] [Full Text] 19. Bousquet J, Price D, et al. Advances in pharmacotherapy for the treatment of allergic rhinitis; MP29-02 (a novel formulation of

azelastine hydrochloride and fluticasone propionate in an advanced delivery system) fills the gaps. Expert Opin Pharmacother 2015; 16(6): 913-28. [PubMed] [Full Text]

20. Price D, et al. Real-world research and its importance in respiratory medicine. Breathe (Sheff) 2015; 11(1): 26-38. [PubMed] [Full Text]

21. van Aalderen WM, Price D, et al. How to match the optimal currently available inhaler device to an individual child with asthma or recurrent wheeze. NPJ Prim Care Respir Med 2015; 8(25): 14088. [PubMed] [Full Text]

22. Bousquet J, Price D, et al. Dymista®: in a class of its own for the treatment of allergic rhinitis. Key Opinions in Medicine 2015. [Full Text]

23. Price D. Expert Review: The significance of inhaler technique and how to improve it. ONdrugDelivery 2014; 53: 4-7. [Full Text] 24. Bousquet J, Price D, et al. Systems medicine approaches for the definition of complex phenotypes in chronic diseases and

ageing. From concept to implementation and policies. Curr Pharm Des 2014; 20(38): 5928-44. [PubMed] [Full Text] 25. Zibrak JD, Price D. Interstitial lung disease: raising the index of suspicion in primary care. NPJ Prim Care Respir Med 2014;

24: 14054. [PubMed] [Full Text] 26. Price D, et al. Is there a rationale and role for long-acting anticholinergic bronchodilators in asthma? NPJ Prim Care Respir

Med 2014; 24: 14023. [PubMed] [Full Text] 27. Price D, Hillyer EV. Fluticasone propionate/formoterol fumarate in fixed-dose combination for the treatment of asthma. Expert

Rev Respir Med 2014; 8(3): 275-91. [PubMed] [Full Text] 28. Bjermer L, Price D, et al. Current evidence and future research needs for FeNO measurement in respiratory diseases. Respir

Med 2014; 108(6): 830-41. [PubMed] [Full Text] 29. Price D, et al. Integrating evidence for managing asthma in patients who smoke. Allergy Asthma Immunol Res 2014; 6(2):

114–20. [PubMed] [Full Text] 30. Roche N, Price D, et al. Quality standards for real-world research. Focus on observational database studies of comparative

effectiveness. Ann Am Thorac Soc 2014; 11(Suppl 2): S99-104. [PubMed] [Full Text] 31. Price D, et al. Complementing the randomized controlled trial evidence base. Evolution not revolution. Ann Am Thorac Soc

2014; 11(Suppl 2): S92-8. [PubMed] [Full Text] 32. Martin R, Price D, et al. The arch conference declaration. Helping to further the science of pragmatic research. Ann Am

Thorac Soc 2014; 11(Suppl 2): S83-4. [PubMed] [Full Text] 33. Bousquet J, Price D, et al. Systems medicine approaches for the definition of complex phenotypes in chronic diseases and

ageing: from concept to implementation and policies. Curr Pharm Des 2014; 20(38): 5928-44. [PubMed] [Full Text] 34. Dekhuijzen PNR, Price D, et al. Prescription of inhalers in asthma and COPD: towards a rational, rapid and effective

approach. Respir Med 2013; 107(12): 1817-21. [PubMed] [Full Text] 35. Roche N, Price D, et al.; Respiratory Effectiveness Group. Integrating real-life studies in the global therapeutic research

framework. Lancet Respir Med 2013; 1(10): e29-30. [PubMed] [Full Text] 36. Price D, Brusselle G. Challenges of COPD diagnosis. Expert Opin Med Diagn 2013 Nov; 7(6): 543-56. [PubMed] [Full Text] 37. Roche N, Price D, et al. Effectiveness of inhaler devices in adult asthma and COPD. Euro Med J 2013; 1: 64-71. [Full Text] 38. Price D, et al. Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD. Prim Care Respir J 2013; 22(1): 92-100.

[PubMed] [Full Text] 39. Price D, et al. Efficacy versus effectiveness trials: informing guidelines for asthma management. Curr Opin Allergy Clin

Immunol 2013; 13(1): 50-7. [PubMed] [Full Text] 40. Bonini M, Price D, et al. What we should learn from the London Olympics. Curr Opin Allergy Clin Immunol 2013; 13(1): 1-3.

[PubMed] [Full Text]

11

41. Inhaler Error Steering Committee, Price D, Bousquet J, et al. Inhaler competence in asthma: common errors, barriers to use and recommended solutions. Respir Med 2013; 107(1): 37-46. [PubMed] [Full Text]

42. Price D, et al. Real-life asthma strategies: the missing piece in the jigsaw. Treatment Strategies - Respiratory 2013; 3(2): 37-46.

43. Price D, Bousquet J. Real-world perceptions of inhaled corticosteroid/long-acting β(2)-agonist combinations in the treatment of asthma. Respir Med 2012; 106(Suppl 1): S4-8. [PubMed] [Full Text]

44. Price D, et al. Reassessing the evidence hierarchy in asthma: evaluating comparative effectiveness. Curr Allergy Asthma Rep 2011; 11(6): 526-38. [PubMed] [Full Text]

45. Decramer M, Price D, et al. New horizons in early stage COPD: improving knowledge, detection and treatment. Respir Med 2011; 105(11): 1576-87. [PubMed] [Full Text]

46. Sims EJ, Price D, et al. Current control and future risk in asthma management. Allergy Asthma Immunol Res 2011; 3(4): 217-25. [PubMed] [Full Text]

47. Price D, et al. Differences between asthma and COPD: how to make the diagnosis in primary care. Hot Topics in Respiratory Medicine 2011; 16: 7-14.

48. Jones R, Price D, et al. Role of clinical questionnaires in optimizing everyday care of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2011; 6: 289-96. [PubMed] [Full Text]

49. Price D, et al. Earlier diagnosis and earlier treatment of COPD in primary care. Prim Care Respir J 2011; 20(1): 15-22. [PubMed] [Full Text]

50. Price DB, et al. Improving the differential diagnosis of chronic obstructive pulmonary disease in primary care. Mayo Clin Proc 2010; 85(12): 1122-9. [PubMed] [Full Text]

51. Price D, et al. The use of roflumilast in COPD: a primary care perspective. Prim Care Respir J 2010; 19(4): 342-51. [PubMed] [Full Text]

52. Haughney J, Price D, et al. Choosing inhaler devices for people with asthma: current knowledge and outstanding research needs. Respir Med 2010; 104(9): 1237-45. [PubMed] [Full Text]

53. Price D. Asthma and allergic rhinitis: linked in treatment and outcomes. Ann Thorac Med 2010; 5(2): 63-4. [PubMed] [Full Text]

54. Pinnock H, Price D, et al. Setting the standard for routine asthma consultations: a discussion of the aims, process and outcomes of reviewing people with asthma in primary care. Prim Care Respir J 2010; 19(1): 75-83. [PubMed] [Full Text]

55. Price D. Spirometry and questionnaire use for early diagnosis of chronic obstructive pulmonary disease. Hot Topics in Respiratory Medicine 2010; 5: 13-8.

56. Price D, Siddall R. COPD management: new and existing therapy options. Future Prescriber 2010; 11(1): 12-6. [Full Text] 57. Costa DJ, Price D, et al. Guidelines for allergic rhinitis need to be used in primary care. Prim Care Respir J 2009; 18(4): 250-

7. [PubMed] [Full Text] 58. Chrystyn H, Price D. Not all asthma inhalers are the same: factors to consider when prescribing an inhaler. Prim Care Respir

J 2009; 18(4): 243-9. [PubMed] [Full Text] 59. Hodder R, Price D. Patient preferences for inhaler devices in chronic obstructive pulmonary disease: experience with

Respimat® Soft Mist™ Inhaler. Int J Chron Obstruct Pulmon Dis 2009; 4: 381-90. [PubMed] [Full Text] 60. Soriano JB, Price D, et al. Screening for and early detection of chronic obstructive pulmonary disease. The Lancet 2009;

374(9691): 721-32. [PubMed] [Full Text] 61. Price D, et al. Spirometry in primary care case-identification, diagnosis and management of COPD. Prim Care Respir J 2009;

18(3): 216-23. [PubMed] [Full Text] 62. Chrystyn H, Price D. What you need to know about inhalers and how to use them. Prescriber 2009; 20(12): 4-52. [Full Text] 63. Price D, et al. Biochemical properties, pharmacokinetics and pharmacological response of tiotropium in chronic obstructive

pulmonary disease patients. Expert Opin Drug Metab Toxicol 2009; 5(4): 417-24. [PubMed] [Full Text] 64. Holgate S, Price D, et al. The Brussels Declaration: the need for change in asthma management. Eur Respir J 2008; 32(6):

1433-42. [PubMed] [Full Text] 65. Haughney J, Price D, et al. Achieving asthma control in practice: understanding the reasons for poor control. Respir Med

2008; 102(12): 1681-93. [PubMed] [Full Text] 66. Thomas M, Price D. Impact of comorbidities on asthma. Expert Rev Clin Immunol 2008; 4(6): 731-42. [PubMed] [Full Text] 67. Bush A, Price D. Pro-con debate: Inhaled corticosteroids should not be prescribed in primary care to children under two years

of age - the case for. Prim Care Respir J 2008; 17(3): 176-80. [PubMed] [Full Text] 68. Price D. The use of omalizumab in asthma. Prim Care Respir J 2008; 17(2): 62-72. [PubMed] [Full Text] 69. Cruz AA, Price D, et al.; ARIA Initiative Scientific Committee. Common characteristics of upper and lower airways in rhinitis

and asthma: ARIA update, in collaboration with GA2LEN. Allergy 2007; 62(Suppl 84): 1-41. [PubMed] [Full Text] 70. Horne R, Price D, et al. Can asthma control be improved by understanding the patient's perspective?. BMC Pulm Med 2007;

7: 8. [PubMed] [Full Text] 71. Price D, Holgate ST. Improving outcomes for asthma patients with allergic rhinitis: conclusions from the MetaForum

conferences. BMC Pulm Med 2006; 6(Suppl 1): S7. [PubMed] [Full Text] 72. Price D, Thomas M. Breaking new ground: challenging existing asthma guidelines. BMC Pulm Med 2006; 6(Suppl 1): S6.

[PubMed] [Full Text] 73. Holgate ST, Price D, et al. Asthma out of control? A structured review of recent patient surveys. BMC Pulm Med 2006;

6(Suppl 1): S2. [PubMed] [Full Text] 74. Price D. The effect of tiotropium bromide on health-related quality of life in chronic obstructive pulmonary disease. Expert Rev

Pharmacoecon Outcomes Res 2006; 6(4): 391-405. [PubMed] [Full Text] 75. Price D. Impact of antibiotic restrictions: the physician’s perspective. Clin Microbiol Infect 2006; 12(Suppl 5): 3-9. [PubMed]

[Full Text] 76. Freeman D, Price D. ABC of chronic obstructive pulmonary disease. Primary care and palliative care. BMJ 2006; 333(7560):

188-90. [PubMed] [Full Text]

12

77. Passalacqua G, Price D, et al. ARIA update: I—Systematic review of complementary and alternative medicine for rhinitis and asthma. J Allergy Clin Immunol 2006; 117(5): 1054-62. [PubMed] [Full Text]

78. Price D. The way forward: dry powder inhalers should only be switched with physician agreement and patient training. Int J Clin Pract 2005; 59(Suppl 149): 36-7. [PubMed] [Full Text]

79. Price D. Do healthcare professionals think that dry powder inhalers can be used interchangeably? Int J Clin Pract Suppl 2005; (149): 26-9. [PubMed] [Full Text]

80. Price D, et al. Could interchangeable use of dry powder inhalers affect patients? Int J Clin Pract Suppl 2005; (149): 3-6. [PubMed] [Full Text]

81. Price D, et al. Progressive breathlessness in COPD - The role of hyperinflation and its pharmacological management. Prim Care Respir J 2005; 14(6): 285-93. [PubMed] [Full Text]

82. Price D, Cross S. Clinical management. Getting up to scratch. Health Serv J 2005; 115(5962): 30-2. [PubMed] 83. Buhl R, Price D. Patients’ perceptions of well-being using a guided self-management plan in asthma. Int J Clin Pract 2004;

58(Suppl 141): 26-32. [Full Text] 84. Reid J, Price D, et al. Development of a primary-care tool to assess treatment success in COPD: consensus report from a

closed meeting of respiratory and primary-care specialists. Prim Care Respir J 2004; 13(2): 99-104. [PubMed] [Full Text] 85. Price D. Measuring the effectiveness of asthma therapy. European Respiratory Review 2004; 13: 98-101. 86. Price D, et al. The importance of preserving choice in inhalation therapy: the CFC transition and beyond. Journal of Drug

Assessment 2004; 7: 45-61. 87. Burney P, Price D, et al. The pharmacoepidemiology of COPD: recent advances and methodological discussion. Eur Respir J

Suppl 2003; 43: 1s-44s. [PubMed] [Full Text] 88. Price D. Chronic obstructive pulmonary disease – issues in primary care. N Z Fam Physician 2003; 30(3): 162-4. 89. Thomas M, Price D, et al. Database studies in asthma pharmacoeconomics: uses, limitations and quality markers. Expert

Opin Pharmacother 2003; 4(3): 351-8. [PubMed] [Full Text] 90. Cleland J, Price D, et al. Pharmacoeconomics of asthma treatment. Expert Opin Pharmacother 2003; 4(3): 311-8. [PubMed]

[Full Text] 91. Williams S, Price D, et al. General practitioners with a special clinical interest: a model for improving respiratory disease

management. Br J Gen Pract 2002; 52(483): 838-43. [PubMed] 92. Duerden M, Price D. Inhalers: education and training needs. Curr Ther (Seaforth) 2002; 43(5): 21-6, 28-9. 93. Duerden M, Price D. Training issues in inhaler use. N Ethicals J 2001; 4(11): 31-42. 94. Freeman D, Price D. Implications of health economics for prescribers. Respiratory Care Matters 2001; 6(2): 12-3. 95. Duerden M, Price D. Training Issues in the use of inhalers. Disease Management and Health Outcomes 2001; 9(2): 75-87.

[Full Text] 96. Price D. Choices at step 3: increase corticosteroid, add in beta- agonist or add in leukotriene receptor antagonist?. RSM

Suppl 2000. 97. Price D. Tolerability of montelukast. Drugs 2000; 59(Suppl 1): 35-42. [PubMed] [Full Text] 98. Price D. Limitations of anti-inflammatory asthma treatments - Concerns of asthma nurses. Prescriber Suppl 1998. 99. Price D. GPs’ frustrations. Prescriber Suppl 1998. 100. Price D. GPs get new choice in management strategy. RX Magazine 1998; 1(1): 15. 101. Price D. COPD takes its toll. Chemist & Druggist (The Newsweekly for Pharmacy) 1997. 102. Price D. What are the cost implications of intensive primary care asthma management? Re:fund (Magazine of the West

Midlands Association Fundholding Practices) 1997; 14: 19. 103. Gray P, Price D, et al. Occupational asthma in a new employee. Practitioner 1996; 240(1568): 619-22, 625. 104. Price D. Patient attitudes to asthma medications. Respiratory Disease in Practice 1995; 12(4): 13-6. 105. Price D. Steroid phobia. Respiratory Disease in Practice 1994; 11(3): 10-3.

Editorials 1. Hillyer EV, Price DB, et al; on behalf of the Respiratory Effectiveness Group, Small Airways Study Group. Harmonizing the

nomenclature for therapeutic aerosol particle size. J Aerosol Med Pulm Drug Deliv 2017; 31: 1-3.

2. van Boven JFM, Price DB, et al. Urging Europe to put non-adherence to inhaled respiratory medication higher on the policy agenda: a report from the First European Congress on Adherence to Therapy. Eur Respir J 2017; 49(5): 1700076. [PubMed] [Full Text]

3. Bardin PG, Price D, et al. Managing asthma in the era of biological therapies. Lancet Respir Med 2017; 5(5): 376-8. [PubMed] [Full Text]

4. Winchester CC, Price D, et al. A practical tool for primary care antimicrobial stewardship in children. Lancet Respir Med 2016; 4(11): 850-2. [PubMed] [Full Text]

5. Van Ganse E, Price D. Respiratory medication adherence: toward a common language and a shared vision. J Allergy Clin Immunol Pract 2016; 4(5): 799-801. [PubMed] [Full Text]

6. Price DB. Time to get real: critical and imperative change required in evidence evaluation. J Thorac Dis 2016; 8(Suppl 5): S431-4. [PubMed] [Full Text]

7. Price D. Letter from the editor. European Respiratory and Pulmonary Diseases 2015; 1(1): 13. [Full Text] 8. Steenbruggen I, Price D, et al. A BOLD statement on how to case-find moderate/severe COPD. Eur Respir J 2013; 41: 503-4.

[PubMed] [Full Text] 9. Sims EJ, Price D. Spirometry: an essential tool for screening, case-finding, and diagnosis of COPD. Prim Care Respir J 2012;

21(2): 128-30. [PubMed] [Full Text] 10. Lenney W, Price D, et al. Clinical trials and tribulations: the MASCOT study. Thorax 2011; 66(6): 457-8. [PubMed] [Full Text] 11. Papi A, Price D, et al. Inhaler devices for asthma: a call for action in a neglected field. Eur Respir J 2011; 37(5): 982-5.

[PubMed] [Full Text]

13

12. Haughney J, Price D, et al. Improving clinician-patient communication in asthma: the HARP project. Allergy 2010; 65(4): 413-4. [PubMed] [Full Text]

13. Haughney J, Price D, et al. Driving asthma care in Europe: the Brussels Declaration. Prim Care Respir J 2009; 18(2): 55-6. [PubMed] [Full Text]

14. Crockett A, Price D. Co-morbid disease in COPD – more than a coincidence. Int J Chron Obstruct Pulmon Dis 2007; 2(4): 399-400. [PubMed]

15. Levy ML, Price D, et al.; UK General Practice Airways Group (GPIAG). The UK General Practice Airways Group (GPIAG): its formation, development, and influence on the management of asthma and other respiratory diseases over the last twenty years. Prim Care Respir J 2007; 16(3): 132-9. [PubMed] [Full Text]

16. Price D. Editorial: - Allergic rhinitis and asthma. Drugs in Context 2006; 2(10): 415. 17. Price D. Foreword: Can dry powder inhalers be used interchangeably?. Int J Clin Pract 2005; 59(Suppl 149): 1. [Full Text] 18. Cleland J, Price D. Achieving optimal asthma control: can this be informed by recent studies of professional–patient

communication?. Prim Care Respir J 2005; 14(5): 233-5. [PubMed] [Full Text] 19. Ryan D, Price D. Editorial – Allergic rhinitis. Drugs in Context 2005; 1(11): 579. 20. Price D, Duerden M. Chronic obstructive pulmonary disease: the lack of a national service framework should not allow us to

ignore it. BMJ 2003; 326(7398): 1046-7. [PubMed] [Full Text] 21. Price DB. Foreword. Clin Drug Investig 2002; 22(Suppl 2). 22. Price D. Health care utilisation for respiratory symptoms. Prim Care Respir J 2001; 10(3): 56-7. 23. Price D. The next three years. Asthma in Gen Prac 1999; 7(2): 25. 24. Ryan D, Price D, et al. New GPIAG chair in primary care respiratory medicine to be hosted at Aberdeen. Asthma in Gen Prac

1999; 7(1): 2.

Books and Book Chapters 1. Thomas M, Price D, et al. A randomised controlled study of the effectiveness of breathing retraining exercises taught by a

physiotherapist either by instructional DVD or in face-to-face sessions in the management of asthma in adults, 21 ed. Winchester: NIHR Journals Library; 2017.

2. Soriano JB, Price D. Screening and case finding. Anzueto A, Heijdra Y, Hurst JR (eds). Controversies in COPD, 69 ed. : ERS Monograph; 2015. pp. 1-25. [Full Text]

3. Gruffydd-Jones K, Price D, et al. The 10-minute consultation: chronic obstructive pulmonary disease. London, UK: Cedilla Publishing Ltd; 2008. [Full Text]

4. Freeman D, Price D. Primary care. Stockley R, Rennard S, Rabe K, Celli B (eds). Chronic obstructive pulmonary disease. Massachusetts: Blackwell Publishing; 2007. pp. 579-84. [Full Text]

5. Freeman D, Price D. Primary care and palliative care. Currie GP (ed). ABC of COPD. Oxford, UK: Blackwell Publishing; 2007. pp. 31–3. [Full Text]

6. Price D. The one-airway concept. Haughney J (ed). A primary care guide to allergy. Dartford: Magister Consulting; 2006. 7. Bull E, Price D. A simple guide to asthma. Bull E, Price D (eds). Long Hanborough: CSF Medical Communications; 2005. [Full

Text] 8. Thomas M, Price D. Asthma drug treatment patient notes. Kassianos G, Chung F, Grufffydd-Jones K, Thomas M, Price D

(eds). Best medicine: asthma. Long Hanborough: CSF Medical Communications; 2005. pp. 297-302. 9. Thomas M, Price D. Asthma patient notes. Kassianos G, Chung F, Grufffydd-Jones K, Thomas M, Price D (eds). Best

medicine: asthma. Long Hanborough: CSF Medical Communications; 2005. pp. 21-4. 10. Price D, et al. Churchill's in clinical practice series: COPD and asthma. Edinburgh: Churchill Livingstone; 2004. 11. Thomas M, Price D. The diagnosis and assessment of asthma in primary care. O'Connor B, Scadding G (eds). Key advances

in the clinical management of asthma 2. London: Royal Society of Medicine Press; 2004. pp. 23-9.

12. Cleland J, Price D, et al. Use of nebulizers in primary care: issues and challenges. Boe J, O'Driscoll BR, Dennis JH (eds). Practical handbook of nebulizer therapy. London: Martin Dunitz; 2004. pp. 211-32. [Full Text]

13. Price D. What are the issues in delivering care in primary care?. Johnston SL, Holgate ST (eds). Asthma: critical debates. Oxford: Blackwell Science; 2002. pp. 319-42. [Full Text]

Reports 1. Donner CF, Price D, et al. Inhalation therapy in the next decade: determinants of adherence to treatment in asthma and

COPD. Monaldi Arch Chest Dis 2018; 88(886): 14-36. [Full Text] 2. Bousquet J, Price D, et al. CHRODIS criteria applied to the MASK (MACVIA-ARIA Sentinel NetworK) Good Practice in allergic

rhinitis: a SUNFRAIL report. Clin Transl Allergy 2017; 7: 37. [PubMed] [Full Text] 3. Chisholm A, Price DB, et al. 2016 Respiratory Effectiveness Group annual summit report — impact & influence of real-world

respiratory evidence. J Thorac Dis 2016; 8(Suppl 5): S435-S444. [PubMed] [Full Text] 4. Muraro A, Price D, et al. European symposium on precision medicine in allergy and airways diseases: report of the European

Union parliament symposium (October 14, 2015). Allergy 2015; 71(5): 583-7. [PubMed] [Full Text] 5. Muraro A, Price D, et al. European symposium on precision medicine in allergy and airways diseases: report of the European

Union parliament symposium (October 14, 2015). Rhinology 2015; 53(4): 303-7. [PubMed] [Full Text] 6. Price D, van der Molen T. The Aberdeen primary care COPD research needs statement March 2001. Prim Care Respir J

2001; 10(2): 47-9. 7. Thoonen BPA, Price D, et al. Present and future management of asthma and COPD: proceedings from WONCA 1998. Fam

Pract 1999; 16(3): 313-5. [PubMed] [Full Text]

Letters 1. Kerkhof M, Price DB. Reply [The effect of smoking on exacerbation risk in eosinophilic patients with chronic obstructive

pulmonary disease]. Eur Respir J 2017; 50: 1702086. [PubMed] [Full Text]

14

2. Kerkhof M, Price DB, et al. Blood eosinophil count and exacerbation risk in patients with COPD. Eur Respir J 2017; 50(1): 1700761. [PubMed] [Full Text]

3. Guilbert TW, Price DB. Reply [Impact of spacers on therapeutic ratio with inhaled corticosteroids]. J Allergy Clin Immunol Pract 2017; 5(4): 1163-4. [Full Text]

4. Grigg J, Price DB, et al. Urinary prostanoids in preschool wheeze. Eur Respir J 2017; 49(2): 1601390. [PubMed] [Full Text] 5. Lipworth B, Price DB, et al. It is important to distinguish between HFrEF and HFpEF when interpreting these data. Heart 2016;

102(23): 1934. [PubMed] [Full Text] 6. Price DB, et al. Cost comparison of asthma treatments in 12-week study: caution about matching and short observational

follow-up. Multidiscip Respir Med 2016; 11: 39. [Full Text] 7. van Boven JFM, Price DB, et al. COPD case finding: effective, but also cost-effective?. Lancet Respir Med 2016; 4(10): e49.

[PubMed] [Full Text] 8. Price DB, et al. Inhaled corticosteroid dose-response on blood eosinophils in asthma – Authors’ reply. Lancet Respir

Med 2016; 4(1): e1-2. [PubMed] [Full Text] 9. Van Aalderen WMC, Price DB, et al. Reply [Inhaled corticosteroids for asthma therapy in young children: does aerosol particle

size matter?]. J Allergy Clin Immunol Pract 2016; 4(2): 372-3. [Full Text] 10. Price D, Chrystyn H. Concept review of dry powder inhalers: correct interpretation of published data. Multidiscip Respir

Med 2015; 10:36. [PubMed] [Full Text] 11. Roche N, Price DB, et al. Differential effects of inhaled corticosteroids in smokers/ex-smokers and nonsmokers with

asthma. Am J Respir Crit Care Med 2015; 191(8): 960-4. [PubMed] [Full Text] 12. Price D, et al. Feasibility and ethics. Am J Respir Crit Care Med 2013; 188(11): 1368-9. [PubMed] [Full Text] 13. Jones R, Price D, et al. GOLD COPD categories are not fit for purpose in primary care. Lancet Respir Med 2013; 1(1): e17.

[PubMed] [Full Text] 14. Price D, et al. The authors reply [Leukotriene antagonists in asthma]. N Engl J Med 2011; 365(3): 273-4. [Full Text] 15. Jones RC, Price DB, et al. Implementing the change in National Institute for Health and Clinical Excellence guidance on

airflow obstruction grading in chronic obstructive pulmonary disease. Thorax 2011; 66: 543-4. [Full Text] 16. Winchester CC, Price D, et al. Flawed comparative groups lead to flawed conclusions: response. Chest 2009; 136(4): 1185-6.

[Full Text] 17. Thomas M, Price D. High-dose inhaled corticosteroid versus long-acting beta-agonist addition in asthma. Chest 2009; 135(5):

1404–5. [PubMed] [Full Text] 18. Cleland JA, Price DB. Implementing self-management plans for asthma patients. Prescriber 2004; 15: 76-9. 19. Price DB, et al. Letter to the editor [Association between antibiotic prescribing trends in general practice and community-

acquired pneumonia mortality]. Respir Med 2004; 98(8): 801-3. [Full Text] 20. Thomas M, Price D. Asthma natural history and diagnosis. Ann Fam Med 2004. [Full Text] 21. Price D. My job as a respiratory professional. The Airways Journal 2003; 1. 22. Thomas M, Price D. Prenatal antibiotic exposure and subsequent atopy. Am J Resp Crit Care Med 2003; 167(11): 1578-9.

[Full Text] 23. Pinnock H, Price D, et al. Authors' reply [Routine telephone review of asthma: further investigation is required]. BMJ 2003;

326(7401): 1267-8. [Full Text] 24. Thomas M, Price D. Chronic cough. Article is not consistent with WHO initiative on rhinitis and asthma. BMJ 2003; 326(7397):

1036. [PubMed] [Full Text] 25. Thomas M, Price D. Consistent rhinitis advice needed. BMJ 2003; 326(7383): 261. [Full Text] 26. Thomas M, Price D, et al. Cost effectiveness of asthma management strategies. Pharmacoeconomics 2002; 20(11): 789.

[PubMed] [Full Text] 27. Price D. Pragmatic randomised controlled trials. Prim Care Respir J 2002; 11(2): 78. [Full Text] 28. Partridge M, Price D, et al. Guided self management plans for asthma. Advice should be simple and patient focused.

BMJ 2001; 322(7294): 1121-2. [PubMed] [Full Text]